CN104398867B - A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease - Google Patents
A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease Download PDFInfo
- Publication number
- CN104398867B CN104398867B CN201410582936.XA CN201410582936A CN104398867B CN 104398867 B CN104398867 B CN 104398867B CN 201410582936 A CN201410582936 A CN 201410582936A CN 104398867 B CN104398867 B CN 104398867B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- heart disease
- coronary heart
- arrhythmia cordis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease, the pharmaceutical composition is prepared by traditional Chinese medicinal material raw materials and pharmaceutically acceptable auxiliaries, by weight, described traditional Chinese medicinal material raw materials include 39 56 parts of longan seed, 21 30 parts of glutinous rice root, 15 25 parts of cordate houttuynia, 21 30 parts of dry land grass, 8 16 parts of bicolor, 59 parts of carbonized hair, 59 parts of cortex acanthopanacis, 59 parts of Flos Magnoliae Officinalis, 1.5 3 parts of the root of gansui, 7 12 parts of tangerine leaf, 7 12 parts of paniculate swallowwort.After pharmaceutical composition involved in the present invention is treated to arrhythmia cordis patients with coronary heart disease, positive effect is better than the Western medicine such as metoprolol, and without obvious adverse reaction or toxic side effect, more security in therapeutic process.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to a kind of medicine group for treating arrhythmia cordis coronary heart disease
Compound.
Background technology
Coronary heart disease is that a kind of coronary artery stenosis triggered by a variety of causes causes irrigated myocardial ischemia, necrosis
One group of clinical syndrome.Coronary heart disease is higher in the incidence of disease of developed country, therefore is referred to as " number one killer ".The disease is in person in middle and old age
In it is relatively conventional, and the incidence of disease gradually rises trend.According to the prediction of the World Health Organization, to the year two thousand twenty, angiocardiopathy
The big fatal disease of the first in the world will be turned into.It can be seen that coronary heart disease has turned into influences middle-aged and old life and healths and quality of life
One of chief complaint.
Coronary heart disease is the common disease factor of arrhythmia cordis, and arrhythmia cordis is one of clinical manifestation of coronary heart disease again, with room property and
The arrhythmia cordis of Premature atrial contraction is most commonly seen.When Premature Ventricular Beats betide acute ischemia or infarct, such as angina pectoris and
Acute myocardial infarction AMI；Also the heart caused by old myocardial infarction, aneurysm and chronic ischemic myocardial disease can be betided expands
Greatly, situations such as heart failure.Premature atrial contraction does not form influence more on patient in itself, but the proiosystole that takes place frequently is probably atrium
The performance that myocardial ischemia aggravates or cardiac insufficiency, atrial pressure increase.The atrial arrhythmia that patients with coronary heart disease has clinical meaning is
Auricular fibrillation.Auricular fibrillation can be secondary to sinus bradycardia, it is also possible to which heart muscle ischemic injuries, atrial expansion cause the heart
Caused by myoelectricity unstable generation multiple location in room is turned back.When auricular fibrillation occurs for patients with coronary heart disease, because too fast ventricular rate is often led
Myocardial oxygen consumption increase is caused, can aggravate or deteriorate myocardial ischemia, angina pectoris or cardiac insufficiency is induced and produces adverse consequences.
Metoprolol is selective beta receptor blocking agent, by oral administration after can absorb rapidly, absorptivity is up to more than 90%, medicine
Thing concentration can peak in 1.5h, and the continuous action time is 2h, but because its long-time applies rear unexpected drug withdrawal, be easily caused
Conditions of patients deteriorates.Therefore, metoprolol is in the application by a definite limitation.
At present, it is clinical often to use western medicine arrhythmia cordis coronary heart disease, such as enteric coated aspirin, metoprolol.It is this kind of
Anti-arrhythmia Western medicine belongs to chemical synthetic drug more, and quick after patient's medication, therapeutic effect is obvious, but generally occurs not
With the toxic side effect of degree, such as palpitaition, dizziness, insomnia.Plus the costly of PCI, therefore, largely
Limit its application clinically.The invasive method of other other treatment methods, pacemaker, RF ablation, defibrillator etc.
Although also there is certain effect, also costly, many patients are also difficult to bear medical expense, and also therefore, it is difficult to clinically push away
Wide application.Carrying forward and develop with China's tcm cause, remarkable effect is achieved in terms of arrhythmia cordis coronary heart disease is treated, in
Cure treatment arrhythmia cordis coronary heart disease and play more and more important effect.
The content of the invention
It is an object of the invention to by the way that Chinese medicine proved recipe among the people is furtherd investigate and explored, so as to provide a kind for the treatment of
The pharmaceutical composition of arrhythmia cordis coronary heart disease.
The object of the present invention is achieved like this：
A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease, is prepared by traditional Chinese medicinal material raw materials and pharmaceutically acceptable auxiliaries,
By weight, described traditional Chinese medicinal material raw materials include：Longan seed 39-56 parts, glutinous rice root 21-30 parts, cordate houttuynia 15-25 parts, drought
Field grass 21-30 parts, bicolor 8-16 parts, carbonized hair 5-9 parts, cortex acanthopanacis 5-9 parts, Flos Magnoliae Officinalis 5-9 parts, root of gansui 1.5-3 parts, tangerine leaf
7-12 parts, paniculate swallowwort 7-12 parts.
Preferably, the pharmaceutical composition of arrhythmia cordis coronary heart disease is treated as described above, wherein by weight, in described
Medicinal raw material is by longan seed 44-50 parts, glutinous rice root 24-26 parts, cordate houttuynia 19-22 parts, dry land grass 24-26 parts, bicolor 10-13
Part, carbonized hair 6-8 parts, cortex acanthopanacis 6-8 parts, Flos Magnoliae Officinalis 6-8 parts, root of gansui 2-2.5 parts, tangerine leaf 9-10 parts and paniculate swallowwort 9-10 part groups
Into.
In the most preferred embodiment of the present invention, the drug regimen of arrhythmia cordis coronary heart disease is treated as described above
Thing, wherein by weight, described traditional Chinese medicinal material raw materials are by 45 parts of longan seed, 25 parts of glutinous rice root, 20 parts of cordate houttuynia, dry land grass 25
Part, 11 parts of bicolor, 7 parts of carbonized hair, 7 parts of cortex acanthopanacis, 7 parts of Flos Magnoliae Officinalis, 2 parts of the root of gansui, 9 parts of compositions of 9 parts of tangerine leaf and paniculate swallowwort.
The pharmaceutical composition of the present invention is to obtain above-mentioned traditional Chinese medicinal material raw materials by extraction and separation technology there is the anti-rhythm of the heart to lose
The Chinese medical extract of normal bioactivity, then by the extract and acceptable auxiliary material in any or more than one pharmacies
Such as starch, dextrin, lactose, microcrystalline cellulose, HPMC, sodium carboxymethyl starch, magnesium stearate, superfine silica gel powder are mixed
Various formulations made of conjunction, for example, can be made into oral liquid, tablet, sustained release tablets, dripping pill, granule, capsule.Preferred dosage form is
Granule.
It should be noted that traditional Chinese medicinal material raw materials of the pharmaceutical composition of the present invention employed in preparation process are with as follows
Source：Longan seed selects sapindaceous plant longan Dimocarpus longan Lour. dry seed.Glutinous rice root selects standing grain
The dry rhizome of graminaceous plant rice (glutinous rice).Cordate houttuynia selects saururaceae plant houttuynia cordata Houttuynia cordata
Thunb. dry aerial parts.Dry land grass selects Scrophulariaceae Brittle Falsepimpernel Herb platymiscium dry land grass Lindernia ruellioides
(Colsm.) Pennell drying herb.Bicolor selects Myrsinacea Ardisa plant knuckle-tooth Japanese ardisia Ardisia
Crenata Sims. dry root.Carbonized hair selects carbide made of human hair.Cortex acanthopanacis selects Araliaceae acanthopanax gracilistylus
Acanthopanax gracilistylus W.W.Smith dry root skin.Flos Magnoliae Officinalis selects the Magnoliacea plant bark of official magnolia
Magnolia officinalis Rehd.et Wils. dry flower.The root of gansui selects euphorbia plant root of gansui Euphorbia
Kansui Liou.mss. dried root.Tangerine leaf selects rutaceae orange Citrus reticulata Blanco drying
Leaf.Paniculate swallowwort selects Asclepiadaceae Cynanchum plant paniculate swallowwort Cynanchum paniculatum (Bge.) Kitag. drying
Root.
Compared with prior art, pharmaceutical composition involved in the present invention is treated to arrhythmia cordis patients with coronary heart disease
Afterwards, positive effect is better than the Western medicine such as metoprolol, and without obvious adverse reaction or toxic side effect in therapeutic process, it is more safe
Property, there is high application value, clinical practice is worthy to be popularized.
Embodiment
Be below the present invention specific embodiment and clinical practice example, technical scheme and technique effect are done into
One step is described, but protection scope of the present invention is not limited to these embodiments.
The preparation of the Chinese herbal granules of embodiment 1
Longan seed 0.45kg, glutinous rice root 0.25kg, cordate houttuynia 0.20kg, dry land grass 0.25kg, bicolor 0.11kg are weighed,
Carbonized hair 0.07kg, cortex acanthopanacis 0.07kg, Flos Magnoliae Officinalis 0.07kg, root of gansui 0.02kg, tangerine leaf 0.09kg, paniculate swallowwort 0.09kg, close
And add water to cook twice, for the first time plus water volume is 10 times of amounts (L/kg) of medicinal material gross mass, decocts 2h；Second plus water body
Product is 8 times of medicinal material gross mass amounts (L/kg), decocts 1.5h, collecting decoction, 0.08MPa, when being concentrated under reduced pressure into 70 DEG C at 70 DEG C
Relative density is 1.15 or so, adds 95% (v/v) ethanol alcohol content stirring, is stood overnight, is filtered, filtrate up to 75% (v/v)
It is concentrated under reduced pressure under the conditions of 0.08MPa, 65 DEG C to the medicinal extract that relative density at 65 DEG C is 1.20 or so, medicinal extract and puts stainless steel disc
In, vacuum drying (less than 60 DEG C) crushes into dry cream, adds the cane sugar powder and 1 times of dextrin measured of 3 times of amounts, mix, dry method system
Grain, packaging, often wraps 10g.
The preparation of the traditional Chinese medicine oral liquid of embodiment 2
Longan seed 0.50kg, glutinous rice root 0.25kg, cordate houttuynia 0.25kg, dry land grass 0.25kg, bicolor 0.15kg are weighed,
Carbonized hair 0.07kg, cortex acanthopanacis 0.09kg, Flos Magnoliae Officinalis 0.05kg, root of gansui 0.02kg, tangerine leaf 0.10kg, paniculate swallowwort 0.07kg, close
And add water to cook twice, for the first time plus water volume is 10 times of amounts (L/kg) of medicinal material gross mass, decocts 2h；Second plus water body
Product is 8 times of medicinal material gross mass amounts (L/kg), decocts 1.5h, collecting decoction, 0.08MPa, when being concentrated under reduced pressure into 70 DEG C at 70 DEG C
Relative density is 1.15 or so, adds 95% (v/v) ethanol alcohol content stirring, is stood overnight, is filtered, filtrate up to 80% (v/v)
It is 1.15 or so to be concentrated under reduced pressure under the conditions of 0.08MPa, 65 DEG C to relative density at 65 DEG C, adds water and sucrose to be configured to orally
Liquid.
The preparation of the traditional Chinese medicine oral liquid of embodiment 3
Longan seed 0.40kg, glutinous rice root 0.21kg, cordate houttuynia 0.15kg, dry land grass 0.21kg, bicolor 0.10kg are weighed,
Carbonized hair 0.08kg, cortex acanthopanacis 0.06kg, Flos Magnoliae Officinalis 0.05kg, root of gansui 0.02kg, tangerine leaf 0.12kg, paniculate swallowwort 0.12kg, close
And add water to cook twice, for the first time plus water volume is 10 times of amounts (L/kg) of medicinal material gross mass, decocts 2h；Second plus water body
Product is 8 times of medicinal material gross mass amounts (L/kg), decocts 1.5h, collecting decoction, 0.08MPa, when being concentrated under reduced pressure into 70 DEG C at 70 DEG C
Relative density is 1.18 or so, adds 95% (v/v) ethanol alcohol content stirring, is stood overnight, is filtered, filtrate up to 78% (v/v)
It is 1.15 or so to be concentrated under reduced pressure under the conditions of 0.08MPa, 65 DEG C to relative density at 65 DEG C, adds water and sucrose to be configured to orally
Liquid.
The preparation of the Chinese herbal granules of embodiment 4
Longan seed 0.55kg, glutinous rice root 0.30kg, cordate houttuynia 0.20kg, dry land grass 0.30kg, bicolor 0.12kg are weighed,
Carbonized hair 0.06kg, cortex acanthopanacis 0.08kg, Flos Magnoliae Officinalis 0.06kg, root of gansui 0.02kg, tangerine leaf 0.07kg, paniculate swallowwort 0.10kg, close
And add water to cook twice, for the first time plus water volume is 10 times of amounts (L/kg) of medicinal material gross mass, decocts 2h；Second plus water body
Product is 8 times of medicinal material gross mass amounts (L/kg), decocts 1.5h, collecting decoction, 0.08MPa, when being concentrated under reduced pressure into 70 DEG C at 70 DEG C
Relative density is 1.15 or so, adds 95% (v/v) ethanol alcohol content stirring, is stood overnight, is filtered, filtrate up to 80% (v/v)
It is concentrated under reduced pressure under the conditions of 0.08MPa, 65 DEG C to the medicinal extract that relative density at 65 DEG C is 1.15 or so, medicinal extract and puts stainless steel disc
In, vacuum drying (less than 60 DEG C) crushes into dry cream, adds the cane sugar powder and 1 times of dextrin measured of 3 times of amounts, mix, dry method system
Grain, packaging, often wraps 10g.
The Chinese herbal granules of embodiment 5 were studied the effect of arrhythmia cordis patients with coronary heart disease
Arrhythmia cordis patients with coronary heart disease through making a definite diagnosis 72, Electrocardiogram Feature are Premature Ventricular Beats, Premature atrial contraction
Person, exclude bradycardia, digitalis poisoning, chamber or the rhythm of the heart caused by the block of room property, electrolyte disturbance and acid-base imbalance
Not normal person.All cases are randomly divided into western medicine group and Chinese medicine test group, every group 36.Control group patient male 25, female
Property 11；Age 45-77 year, average age (63.8 ± 9.5) year；Course of disease 1-6 weeks, average (3.2 ± 0.5) week.Test group is suffered from
Person male 24, women 12, age 45-75 year, average age (65.2 ± 10.2) year；Course of disease 1-7 weeks, average (3.4 ±
0.6) it is all.Two groups of patients compare that there was no significant difference in terms of the general information such as sex, age, the course of disease, have comparativity.
Control group patient gives metoprolol tablets treatment, daily orally once, each 47.5mg, continuously takes two weeks；Examination
Test group patient to take after mixing it with water the Chinese herbal granules (preparing according to the formulation and technology of the embodiment of the present invention 1) of the present invention, daily sooner or later each 1
It is secondary, 1 wrap every time, two weeks are a course for the treatment of, persistently take a course for the treatment of.After treatment end, curative effect is judged by following standard：(1) cure：
Arrhythmia cordis, clinical symptoms are wholly absent.(2) effectively：Arrhythmia episode gap extension, clinical symptoms substantially disappear.(3) nothing
Effect：Arrhythmia cordis phenomenon does not disappear, and clinical symptoms do not occur significant change.Total effective rate=(cure+effectively)/total the example for the treatment of
Number × 100%.Two groups of patient clinical therapeutic effects are relatively shown in Table 1.
Can be seen that control group patient to treat total effective rate according to the treatment results of table 1 is 63.9%, and test group patient controls
It is 97.2% to treat total effective rate, is substantially better than control group the effect of test group.
1 two groups of patient clinical therapeutic effects of table compare [example (%)]
In addition, there is adverse reactions people 3, adverse reaction rate 8.3%, experiment during treatment in control group patient
Adverse reactions people does not occur for group patient.
Claims (5)
1. a kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease, it is characterised in that by traditional Chinese medicinal material raw materials and pharmaceutically acceptable auxiliaries
It is prepared, by weight, described traditional Chinese medicinal material raw materials are by longan seed 44-50 parts, glutinous rice root 24-26 parts, cordate houttuynia 19-22
Part, dry land grass 24-26 parts, bicolor 10-13 parts, carbonized hair 6-8 parts, cortex acanthopanacis 6-8 parts, Flos Magnoliae Officinalis 6-8 parts, root of gansui 2-2.5
Part, tangerine leaf 9-10 parts and paniculate swallowwort 9-10 parts composition.
2. the pharmaceutical composition of arrhythmia cordis coronary heart disease is treated according to claim 1, it is characterised in that by weight,
Described traditional Chinese medicinal material raw materials are by 45 parts of longan seed, 25 parts of glutinous rice root, 20 parts of cordate houttuynia, 25 parts of dry land grass, 11 parts of bicolor, more than blood
7 parts of charcoal, 7 parts of cortex acanthopanacis, 7 parts of Flos Magnoliae Officinalis, 2 parts of the root of gansui, 9 parts of compositions of 9 parts of tangerine leaf and paniculate swallowwort.
3. the pharmaceutical composition for the treatment of arrhythmia cordis coronary heart disease according to claim 1 or claim 2, it is characterised in that described medicine
Compositions are oral formulations.
4. the pharmaceutical composition of arrhythmia cordis coronary heart disease is treated according to claim 3, it is characterised in that described oral system
Agent is granule.
5. application of the pharmaceutical composition in the medicine for preparing treatment arrhythmia cordis coronary heart disease described in claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410582936.XA CN104398867B (en) | 2014-10-28 | 2014-10-28 | A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410582936.XA CN104398867B (en) | 2014-10-28 | 2014-10-28 | A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104398867A CN104398867A (en) | 2015-03-11 |
| CN104398867B true CN104398867B (en) | 2017-12-19 |
Family
ID=52636576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410582936.XA Expired - Fee Related CN104398867B (en) | 2014-10-28 | 2014-10-28 | A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104398867B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101057949A (en) * | 2006-04-17 | 2007-10-24 | 李源 | Traditional Chinese medicine one-step preparation for treating coronary heart disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004175680A (en) * | 2002-11-25 | 2004-06-24 | Marine Bio Kk | Mineral-containing composition having improving effect on biological balance |
-
2014
- 2014-10-28 CN CN201410582936.XA patent/CN104398867B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101057949A (en) * | 2006-04-17 | 2007-10-24 | 李源 | Traditional Chinese medicine one-step preparation for treating coronary heart disease |
Non-Patent Citations (2)
| Title |
|---|
| 归脾汤加味治疗冠心病合并心率失常的疗效观察;王振生;《四川中医》;20130930;第31卷(第9期);第79-80页 * |
| 用益气养阴、活血调气法治疗冠心病心律失常;张问渠;《湖北中医杂志》;19800331(第3期);第37页右栏 中医辨证，处方 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104398867A (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO335203B1 (en) | Treatment of aspirin resistance with radix sage miltiorrhiaze, its extract and composition. | |
| CN102145060B (en) | Application of traditional Chinese medicine composition in the drugs of the preparation of the coronary heart disease with inquietude and depression | |
| CN102228535B (en) | Application of total saponins and total flavones in preparation of drugs for treating cardiovascular diseases | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN104398867B (en) | A kind of pharmaceutical composition for treating arrhythmia cordis coronary heart disease | |
| Léandre et al. | Effects of leaf decoction from Lophira lanceolata Tiegh. Ex Keay (Ochnaceae) on arterial blood pressure and electrocardiogram in anesthetized rabbits | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN115531458A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or treating arrhythmia | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN102258600B (en) | Medicine composition for treating cardiovascular disease | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN100546637C (en) | A kind of Chinese medicine composition for the treatment of coronary heart disease and preparation method thereof | |
| CN104857393A (en) | Pharmaceutical preparation for treating arrhythmia | |
| CN101167767B (en) | Hypericum attenuatum extraction and its application for preparing medicine for treating cardiac diseases | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN115227757B (en) | Application of traditional Chinese medicine composition in preparation of antihypertensive drugs | |
| CN115814020B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof | |
| CN104398919B (en) | A kind of pharmaceutical composition for treating myocardial infarction and its application | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN115337347B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN105267470B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN105833051A (en) | Heart protecting and collateral dredging pharmaceutical composition, preparation containing same and application thereof | |
| CN104940584B (en) | The pharmaceutical composition and its preparation and application and preparation for the treatment of tachyarrhythmia | |
| CN112716992A (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171219 Termination date: 20201028 |